RYTM EVP converts 10,000 RSUs to common stock

Rhythm Pharmaceuticals EVP Yann Mazabraud reported equity award activity involving restricted stock units and common stock.

Rhea-AI Filing Summary

Rhythm Pharmaceuticals EVP Yann Mazabraud reported equity award activity involving restricted stock units and common stock. On February 14, 2026, he exercised or converted 10,000 restricted stock units into 10,000 shares of common stock at a price of $0.00 per share, reflecting the non-cash nature of the award.

After these transactions, he directly held 30,000 restricted stock units and 53,155 shares of common stock. Each restricted stock unit represents a right to receive one share of common stock and vests in four 25% installments on February 14, 2026, February 1, 2027, February 1, 2028, and February 1, 2029.

Insider Trade Summary

10,000 shares exercised/converted

Exercise 2 txns

Insider Mazabraud Yann

Role EVP, Head of International

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 30,000 contracts (Direct); Common Stock — 53,155 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
2. F2. The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RYTM executive Yann Mazabraud report?

Yann Mazabraud reported exercising or converting 10,000 restricted stock units into 10,000 shares of Rhythm Pharmaceuticals common stock at $0.00 per share. This reflects vesting of equity compensation rather than an open-market stock purchase or sale.

How many Rhythm Pharmaceuticals (RYTM) shares does Yann Mazabraud hold after this Form 4?

After the reported transactions, Yann Mazabraud directly holds 53,155 shares of Rhythm Pharmaceuticals common stock. He also holds 30,000 restricted stock units, each representing a contingent right to receive one additional share of common stock in the future, subject to vesting.

What are the vesting terms of Yann Mazabraud’s RYTM restricted stock units?

The restricted stock units vest in four equal 25% installments. Vesting dates are February 14, 2026, February 1, 2027, February 1, 2028, and February 1, 2029. Each vested unit entitles the holder to receive one share of Rhythm Pharmaceuticals common stock.

Did Yann Mazabraud buy or sell RYTM shares on the open market?

The filing shows an exercise or conversion of derivative securities, not an open-market trade. 10,000 restricted stock units were converted into 10,000 shares of common stock at $0.00 per share as part of his equity compensation, with no reported market purchase or sale.

What does each RYTM restricted stock unit held by Yann Mazabraud represent?

Each restricted stock unit represents a contingent right to receive one share of Rhythm Pharmaceuticals common stock. Delivery of shares occurs as the units vest over time according to the disclosed schedule, and the restricted stock units themselves have no expiration date.

Does Yann Mazabraud’s Form 4 indicate any disposition of RYTM shares?

No dispositions are reported in this Form 4. Both transactions are coded as exercises or conversions of derivative securities, resulting in the acquisition of common stock and the reporting of remaining restricted stock units, with no shares shown as sold or otherwise disposed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazabraud Yann

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of International

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2026		M		10,000	A	(1)	53,155	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/14/2026		M			10,000	(2)	(2)	Common Stock	10,000	$0	30,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.